Colorado’s Prescription Drug Affordability Board (PDAB) has issued recommendations to the state legislature aimed at enhancing consumer involvement, adjusting eligibility thresholds, and incorporating additional rebate data into their prescription drug review process.
In a report detailing its 2023 activities, it states, “The Board recommends the General Assembly consider revising section 10-16-1406(1), C.R.S. to allow for consumers to identify prescription drugs for consideration for affordability reviews, recognizing that some parameters regarding this process could and should be established, either in law or in regulations.”
The report also emphasizes the importance of integrating patient voices earlier in the review process. Additionally, the PDAB recommended lowering the current eligibility threshold, which is set at a drug price of at least $30,000 per year, and prioritizing drugs that affect the largest number of patients based on their indication. Read the report.
Last Updated on October 14, 2024 by Aimed Alliance
